DOP2009000222A - Formulaciones estables de anticuerpo - Google Patents
Formulaciones estables de anticuerpoInfo
- Publication number
- DOP2009000222A DOP2009000222A DO2009000222A DO2009000222A DOP2009000222A DO P2009000222 A DOP2009000222 A DO P2009000222A DO 2009000222 A DO2009000222 A DO 2009000222A DO 2009000222 A DO2009000222 A DO 2009000222A DO P2009000222 A DOP2009000222 A DO P2009000222A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- antibody
- formulations
- insulin
- receptor
- stabilization
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 238000009472 formulation Methods 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 2
- 230000006641 stabilisation Effects 0.000 abstract 2
- 238000011105 stabilization Methods 0.000 abstract 2
- 102000038455 IGF Type 1 Receptor Human genes 0.000 abstract 1
- 108010031794 IGF Type 1 Receptor Proteins 0.000 abstract 1
- 239000013011 aqueous formulation Substances 0.000 abstract 1
- 230000002608 insulinlike Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91974407P | 2007-03-22 | 2007-03-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2009000222A true DOP2009000222A (es) | 2009-12-15 |
Family
ID=39766776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2009000222A DOP2009000222A (es) | 2007-03-22 | 2009-09-18 | Formulaciones estables de anticuerpo |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20100260766A1 (enExample) |
| EP (1) | EP2136839A4 (enExample) |
| JP (1) | JP2010522208A (enExample) |
| KR (1) | KR20090113340A (enExample) |
| CN (1) | CN101668540A (enExample) |
| AU (1) | AU2008228823A1 (enExample) |
| BR (1) | BRPI0809112A2 (enExample) |
| CA (1) | CA2681743A1 (enExample) |
| CR (1) | CR11005A (enExample) |
| DO (1) | DOP2009000222A (enExample) |
| EA (1) | EA200970880A1 (enExample) |
| EC (1) | ECSP099642A (enExample) |
| IL (1) | IL200321A0 (enExample) |
| MX (1) | MX2009010179A (enExample) |
| TN (1) | TN2009000382A1 (enExample) |
| UA (1) | UA96473C2 (enExample) |
| WO (1) | WO2008116103A2 (enExample) |
| ZA (1) | ZA200905636B (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160279239A1 (en) | 2011-05-02 | 2016-09-29 | Immunomedics, Inc. | Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| TW200838559A (en) * | 2006-11-29 | 2008-10-01 | Imclone Systems Inc | Insulin-like growth factor-1 receptor antagonists for modulation of weight and liposity |
| PE20090368A1 (es) | 2007-06-19 | 2009-04-28 | Boehringer Ingelheim Int | Anticuerpos anti-igf |
| KR20110079693A (ko) | 2008-10-29 | 2011-07-07 | 와이어쓰 엘엘씨 | 단일 도메인 항원 결합 분자의 정제 방법 |
| MX345226B (es) * | 2008-10-29 | 2017-01-20 | Ablynx Nv | Formulaciones de moleculas de union a antigeno de dominio sencillo. |
| WO2010056804A1 (en) * | 2008-11-12 | 2010-05-20 | Medimmune, Llc | Antibody formulation |
| EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| PE20120415A1 (es) | 2008-12-12 | 2012-05-09 | Boehringer Ingelheim Int | Anticuerpos anti-igf |
| TWI609698B (zh) | 2010-01-20 | 2018-01-01 | Chugai Pharmaceutical Co Ltd | 穩定化的含抗體溶液製劑 |
| WO2012028683A1 (en) | 2010-09-02 | 2012-03-08 | Novartis Ag | Antibody gel system for sustained drug delivery |
| MX351706B (es) * | 2010-09-17 | 2017-10-25 | Baxalta Inc | Estabilizacion de inmunoglobulinas a traves de una formulacion acuosa con histidina a ph acido debil a neutro. |
| CA2813849C (en) | 2010-11-05 | 2021-06-15 | Novartis Ag | Secukinumab for use in the treatment of ankylosing spondylitis |
| EP2704751B1 (en) | 2011-05-02 | 2019-04-17 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
| MX361039B (es) * | 2011-10-26 | 2018-11-26 | Amgen Inc | Métodos para reducir o eliminar modificación de proteína y degradación que surge de la exposición a luz ultravioleta. |
| KR101600733B1 (ko) | 2011-10-28 | 2016-03-09 | 프로테나 바이오사이언시즈 리미티드 | 알파-시누클레인을 인식하는 인간화된 항체 |
| AU2013211874B2 (en) | 2012-01-27 | 2017-11-02 | Prothena Biosciences Limited | Humanized antibodies that recognize alpha-synuclein |
| AR092862A1 (es) * | 2012-07-25 | 2015-05-06 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion |
| AR094821A1 (es) * | 2012-07-25 | 2015-09-02 | Hanmi Pharm Ind Co Ltd | Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada |
| AR091902A1 (es) * | 2012-07-25 | 2015-03-11 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de un conjugado de insulina de accion prolongada |
| UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| NZ707168A (en) | 2012-12-26 | 2016-09-30 | Wockhardt Ltd | Pharmaceutical composition of insulins |
| US20140255413A1 (en) | 2013-03-07 | 2014-09-11 | Boehringer Ingelheim International Gmbh | Combination therapy for neoplasia treatment |
| US9700485B2 (en) | 2013-04-24 | 2017-07-11 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| NL1040254C2 (en) * | 2013-05-17 | 2014-11-24 | Ablynx Nv | Stable formulations of immunoglobulin single variable domains and uses thereof. |
| US10513555B2 (en) * | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| JP6744856B2 (ja) | 2014-04-08 | 2020-08-19 | プロセナ・バイオサイエンシズ・リミテッド | α−シヌクレインを認識する抗体を含む血液脳関門シャトル |
| UA123697C2 (uk) | 2014-12-04 | 2021-05-19 | Янссен Байотек, Інк. | Спосіб лікування гострого мієлоїдного лейкозу шляхом застосування антитіла до cd38 |
| JP6784683B2 (ja) * | 2015-02-09 | 2020-11-11 | ユーシービー バイオファルマ エスアールエル | 医薬製剤 |
| AU2016264725B2 (en) | 2015-05-20 | 2021-05-27 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of light chain amyloidosis and other CD38-positive hematological malignancies |
| AR104847A1 (es) * | 2015-06-17 | 2017-08-16 | Lilly Co Eli | Formulación de anticuerpo anti-cgrp |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| SI3370770T1 (sl) * | 2015-11-03 | 2021-03-31 | Janssen Biotech, Inc. | Subkutane formulacije protiteles proti CD38 in njihove uporabe |
| JP6992262B2 (ja) * | 2016-03-31 | 2022-02-15 | 東ソー株式会社 | 変性抗体測定試薬の製造方法 |
| CN110352201A (zh) | 2017-04-03 | 2019-10-18 | 免疫医疗公司 | 用于癌症疗法的抗体药物缀合物的皮下施用 |
| EP3703749A1 (en) | 2017-10-31 | 2020-09-09 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
| CR20210435A (es) | 2019-02-18 | 2021-09-20 | Lilly Co Eli | Formulación de anticuerpos terapéuticos |
| CN112206320B (zh) * | 2019-07-12 | 2025-02-25 | 鲁南制药集团股份有限公司 | 一种cd47单克隆抗体冻干粉制剂及其制备工艺 |
| CN113967195A (zh) * | 2020-07-22 | 2022-01-25 | 三生国健药业（上海）股份有限公司 | 抗her2/pd1双特异性抗体冻干制剂及其制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0565233A (ja) * | 1991-03-08 | 1993-03-19 | Mitsui Toatsu Chem Inc | モノクローナル抗体含有凍結乾燥製剤 |
| AU675916B2 (en) * | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| WO2002030463A2 (en) * | 2000-10-12 | 2002-04-18 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| EP2270052B8 (en) * | 2001-06-26 | 2018-05-02 | Amgen Inc. | Antibodies to OPGL |
| JP4317010B2 (ja) * | 2001-07-25 | 2009-08-19 | ピーディーエル バイオファーマ，インコーポレイティド | ＩｇＧ抗体の安定な凍結乾燥医薬製剤 |
| WO2003068259A1 (fr) * | 2002-02-14 | 2003-08-21 | Chugai Seiyaku Kabushiki Kaisha | Produits pharmaceutiques en solution contenant des anticorps |
| NZ540971A (en) * | 2003-02-13 | 2008-04-30 | Pfizer Prod Inc | Uses of anti-insulin-like growth factor I receptor antibodies |
| WO2005016970A2 (en) * | 2003-05-01 | 2005-02-24 | Imclone Systems Incorporated | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
| AR046071A1 (es) * | 2003-07-10 | 2005-11-23 | Hoffmann La Roche | Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos |
| DK1656391T3 (da) * | 2003-08-13 | 2011-01-03 | Pfizer Prod Inc | Modificerede humane IGF-1R antistoffer |
| AU2006247039B2 (en) * | 2005-05-19 | 2011-03-03 | Amgen Inc. | Compositions and methods for increasing the stability of antibodies |
| AU2006259536A1 (en) * | 2005-06-15 | 2006-12-28 | Schering Corporation | Anti-IGF1R antibody formulations |
| CN101410137A (zh) * | 2006-03-28 | 2009-04-15 | 霍夫曼-拉罗奇有限公司 | 抗-igf-1r人单克隆抗体制剂 |
-
2008
- 2008-03-20 CA CA002681743A patent/CA2681743A1/en not_active Abandoned
- 2008-03-20 UA UAA200909552A patent/UA96473C2/ru unknown
- 2008-03-20 KR KR1020097019642A patent/KR20090113340A/ko not_active Abandoned
- 2008-03-20 JP JP2009554753A patent/JP2010522208A/ja active Pending
- 2008-03-20 EP EP08744136A patent/EP2136839A4/en not_active Withdrawn
- 2008-03-20 BR BRPI0809112-9A patent/BRPI0809112A2/pt not_active IP Right Cessation
- 2008-03-20 US US12/528,882 patent/US20100260766A1/en not_active Abandoned
- 2008-03-20 EA EA200970880A patent/EA200970880A1/ru unknown
- 2008-03-20 CN CN200880009446A patent/CN101668540A/zh active Pending
- 2008-03-20 MX MX2009010179A patent/MX2009010179A/es not_active Application Discontinuation
- 2008-03-20 WO PCT/US2008/057718 patent/WO2008116103A2/en not_active Ceased
- 2008-03-20 AU AU2008228823A patent/AU2008228823A1/en not_active Abandoned
-
2009
- 2009-08-10 IL IL200321A patent/IL200321A0/en unknown
- 2009-08-13 ZA ZA200905636A patent/ZA200905636B/xx unknown
- 2009-08-28 CR CR11005A patent/CR11005A/es not_active Application Discontinuation
- 2009-09-18 DO DO2009000222A patent/DOP2009000222A/es unknown
- 2009-09-18 TN TNP2009000382A patent/TN2009000382A1/fr unknown
- 2009-09-21 EC EC2009009642A patent/ECSP099642A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP099642A (es) | 2009-11-30 |
| MX2009010179A (es) | 2010-03-15 |
| WO2008116103A3 (en) | 2009-01-08 |
| WO2008116103A2 (en) | 2008-09-25 |
| EP2136839A2 (en) | 2009-12-30 |
| ZA200905636B (en) | 2010-10-27 |
| CA2681743A1 (en) | 2008-09-25 |
| BRPI0809112A2 (pt) | 2014-08-26 |
| JP2010522208A (ja) | 2010-07-01 |
| EP2136839A4 (en) | 2010-04-07 |
| US20100260766A1 (en) | 2010-10-14 |
| IL200321A0 (en) | 2010-04-29 |
| CR11005A (es) | 2010-08-05 |
| UA96473C2 (ru) | 2011-11-10 |
| EA200970880A1 (ru) | 2010-02-26 |
| TN2009000382A1 (en) | 2010-12-31 |
| AU2008228823A1 (en) | 2008-09-25 |
| CN101668540A (zh) | 2010-03-10 |
| KR20090113340A (ko) | 2009-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2009000222A (es) | Formulaciones estables de anticuerpo | |
| AR130402A2 (es) | Formulaciones de anticuerpos anti-pdl1 | |
| AR095451A1 (es) | Formulación de anticuerpos | |
| CY1122181T1 (el) | Φαρμακοτεχνικη μορφη αντισωματος | |
| AR124140A2 (es) | Formulaciones de anticuerpos | |
| CY1124844T1 (el) | Φαρμακευτικο σκευασμα αντισωματος | |
| CY1121420T1 (el) | Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα κατα του υποδοχεα της ιντερλευκινης-6 (il-6r) | |
| CY1121233T1 (el) | Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα καtα του υποδοχεα iντερλευκinης-4(ιl-4r) | |
| WO2012076670A3 (en) | Antibody formulation | |
| ES2676205T3 (es) | Formulaciones estables de anticuerpos para el receptor PD-1 humano de muerte programada y tratamientos relacionados | |
| JOP20190250A1 (ar) | صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب | |
| AR089787A1 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-ang2 | |
| WO2010100200A3 (en) | Lyophilised antibody formulation | |
| WO2011109365A3 (en) | Concentrated protein formulations and uses thereof | |
| PE20120359A1 (es) | Formulacion con anticuerpo | |
| UY32609A (es) | Formulaciones estables de anticuerpos anti-tnf-alfa humanos con grandes concentraciones de proteína | |
| AR095396A1 (es) | Formulaciones de anticuerpo | |
| AR091530A1 (es) | Formulacion farmaceutica liquida de un anticuerpo y acetato | |
| EA201492186A1 (ru) | СОДЕРЖАЩИЕ АНТИТЕЛА К Dll4 СТАБИЛИЗИРОВАННЫЕ КОМПОЗИЦИИ | |
| AR120512A1 (es) | Formulaciones que contienen anticuerpos | |
| ECSP21043639A (es) | Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf | |
| AR130115A2 (es) | Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf | |
| AR122036A2 (es) | Composiciones farmacéuticas estables para la administración intratecal de arisulfatasa a |